OR WAIT 15 SECS
The American Glaucoma Society (AGS) has chosen Thasarat S. Vajaranant, MD, to receive the Thom J. Zimmerman, MD, PhD Memorial Award, supported by Valeant Ophthalmics.
Bridgewater, NJ-The American Glaucoma Society (AGS) has chosen Thasarat S. Vajaranant, MD, to receive the Thom J. Zimmerman, MD, PhD Memorial Award, supported by Valeant Ophthalmics.
The Zimmerman award will support Dr. Vajaranant’s clinical research study, “A Feasibility Study to Assess the Accuracy of Self-reported Glaucoma Outcomes and Participant Interest in Ancillary Glaucoma Studies as Part of the Women’s Health Initiative (WHI) Extension.”
Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC, worked with the AGS to establish the award in memory of Dr. Zimmerman, the developer of the glaucoma medication timolol maleate.
Dr. Zimmerman was emeritus professor and chairman of the Department of Ophthalmology and Visual Sciences and emeritus professor of the Department of Pharmacology and Toxicology at the University of Louisville. He was best known for the development of drugs for treatment of glaucoma, including timolol. With his partner, Chris Paterson, he spearheaded the building of the addition to the Kentucky Lions Eye Center and the Rounsavall Eye Clinic, both in Louisville.
For more articles in this issue of Ophthalmology Times eReport, click here.